SUTRO BIOPHARMA, INC. Debt Securities, Available-for-sale, Amortized Cost
SUTRO BIOPHARMA, INC. (STRO) had Debt Securities, Available-for-sale, Amortized Cost of $162.73 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $162.73M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $202.29M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $134.61M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $166.67M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $162.73M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $202.29M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $134.61M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $166.67M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $203.14M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $247.86M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $313.37M 10-K · filed 2026-03-23 |
| 2024-09-30 | $387.99M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $361.76M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $265.75M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $329.54M 10-K · filed 2025-03-13 |
| 2023-09-30 | $318.98M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $357.79M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $250.20M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $299.03M 10-K · filed 2024-03-25 |
| 2022-09-30 | $287.79M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $184.03M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $192.71M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $228.88M 10-K · filed 2023-03-30 |
| 2021-09-30 | $253.65M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $285.05M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $292.85M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $324.85M 10-K · filed 2022-02-28 |
| 2020-09-30 | $201.65M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $204.49M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $127.46M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $131.50M 10-K · filed 2021-03-18 |
| 2019-09-30 | $148.63M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $165.83M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $184.37M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $195.44M 10-K · filed 2020-03-16 |
| 2018-09-30 | $123.25M 10-Q · filed 2018-11-14 |
| 2017-12-31 | $18.96M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |